GK-1 Improves the Immune Response Induced by Bone Marrow Dendritic Cells Loaded with MAGE-AX in Mice with Melanoma

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2015 Mar 12

PMID 25759825

Citations 11

Authors

Gabriela Pinon-Zarate

Miguel Angel Herrera-Enriquez

Beatriz Hernandez-Tellez

Katia Jarquin-Yanez

Andres Eliu Castell-Rodriguez

Affiliations

Soon will be listed here.

Abstract

The aim of dendritic cell (DC) vaccination in cancer is to induce tumor-specific effector T cells that may reduce and control tumor mass. Immunostimulants that could drive a desired immune response are necessary to be found in order to generate a long lasting tumor immune response. GK-1 peptide, derived from Taenia crassiceps, induces not only increase in TNFα, IFNγ, and MCP-1 production in cocultures of DCs and T lymphocytes but also immunological protection against influenza virus. Moreover, the aim of this investigation is the use of GK-1 as a bone marrow DCs (BMDCs) immunostimulant targeted with MAGE antigen; thus, BMDC may be used as immunotherapy against murine melanoma. GK-1 induced in BMDCs a meaningful increment of CD86 and IL-12. In addition, the use of BMDCs TNFα/GK-1/MAGE-AX induced the highest survival and the smallest tumors in mice. Besides, the treatment helped to increase CD8 lymphocytes levels and to produce IFNγ in lymph nodes. Moreover, the histopathological analysis showed that BMDCs treated with GK-1/TNFα and loaded with MAGE-AX induced the apparition of more apoptotic and necrotic areas in tumors than in mice without treatment. These results highlight the properties of GK-1 as an immunostimulant of DCs and suggest as a potential candidate the use of this immunotherapy against cancer disease.

Citing Articles

Pro-inflammatory responses after peptide-based cancer immunotherapy.

Mahaki H, Ravari H, Kazemzadeh G, Lotfian E, Daddost R, Avan A Heliyon. 2024; 10(11):e32249.

PMID: 38912474 PMC: 11190603. DOI: 10.1016/j.heliyon.2024.e32249.

Suppression of the growth and metastasis of mouse melanoma by and tapeworms.

Schreiber M, Machacek T, Vajs V, Smidova B, Majer M, Hrdy J Front Immunol. 2024; 15:1376907.

PMID: 38571957 PMC: 10987685. DOI: 10.3389/fimmu.2024.1376907.

How tapeworms interact with cancers: a mini-review.

Schreiber M, Vajs V, Horak P PeerJ. 2024; 12:e17196.

PMID: 38563013 PMC: 10984186. DOI: 10.7717/peerj.17196.

Gelatin/Hyaluronic Acid Scaffold Coupled to CpG and MAGE-A5 as a Treatment against Murine Melanoma.

Pinon-Zarate G, Hernandez-Tellez B, Jarquin-Yanez K, Herrera-Enriquez M, Fuerte-Perez A, Valencia-Escamilla E Polymers (Basel). 2022; 14(21).

PMID: 36365602 PMC: 9657831. DOI: 10.3390/polym14214608.

Immunomodulatory Properties of Masticadienonic Acid and 3α-Hydroxy Masticadienoic Acid in Dendritic Cells.

Pinon-Zarate G, Reyes-Riquelme F, Sanchez-Monroy M, Velasco-Torrez M, Martinez-Vazquez M, Cardenas-Monroy C Molecules. 2022; 27(4).

PMID: 35209237 PMC: 8879852. DOI: 10.3390/molecules27041451.

References

Shankaran V, Ikeda H, Bruce A, White J, Swanson P, Old L . IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410(6832):1107-11. DOI: 10.1038/35074122. View

Rosenberg S, Restifo N, Yang J, Morgan R, Dudley M . Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8(4):299-308. PMC: 2553205. DOI: 10.1038/nrc2355. View

Toungouz M, Libin M, Bulte F, Faid L, Lehmann F, Duriau D . Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol. 2001; 69(6):937-43. View

Janeway Jr C . How the immune system works to protect the host from infection: a personal view. Proc Natl Acad Sci U S A. 2001; 98(13):7461-8. PMC: 34691. DOI: 10.1073/pnas.131202998. View

Schuler-Thurner B, Schultz E, Berger T, Weinlich G, Ebner S, Woerl P . Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002; 195(10):1279-88. PMC: 2193752. DOI: 10.1084/jem.20012100. View

Krause S, Neumann C, Soruri A, Mayer S, Peters J, Andreesen R . The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother. 2002; 25(5):421-8. DOI: 10.1097/00002371-200209000-00006. View

Bai L, Beckhove P, Feuerer M, Umansky V, Choi C, Diel I . Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo. Int J Cancer. 2002; 103(1):73-83. DOI: 10.1002/ijc.10781. View

Mullins D, Sheasley S, Ream R, Bullock T, Fu Y, Engelhard V . Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med. 2003; 198(7):1023-34. PMC: 2194213. DOI: 10.1084/jem.20021348. View

Slingluff Jr C, Petroni G, Yamshchikov G, Barnd D, Eastham S, Galavotti H . Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003; 21(21):4016-26. DOI: 10.1200/JCO.2003.10.005. View

10.

Dranoff G . Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004; 4(1):11-22. DOI: 10.1038/nrc1252. View

11.

Parmiani G, Castelli C, Rivoltini L, Casati C, Tully G, Novellino L . Immunotherapy of melanoma. Semin Cancer Biol. 2004; 13(6):391-400. DOI: 10.1016/j.semcancer.2003.09.001. View

12.

Figdor C, de Vries I, Lesterhuis W, Melief C . Dendritic cell immunotherapy: mapping the way. Nat Med. 2004; 10(5):475-80. DOI: 10.1038/nm1039. View

13.

Dunn G, Old L, Schreiber R . The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21(2):137-48. DOI: 10.1016/j.immuni.2004.07.017. View

14.

Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S . Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992; 176(6):1693-702. PMC: 2119469. DOI: 10.1084/jem.176.6.1693. View

15.

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

16.

Fisher D, Medrano E, McMahon M, Soengas M, Schuchter L, Wolchok J . Meeting report: fourth international congress of the Society for Melanoma Research. Pigment Cell Melanoma Res. 2008; 21(1):15-26. DOI: 10.1111/j.1755-148X.2007.00437.x. View

17.

Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S . Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res. 2008; 68(10):3931-40. DOI: 10.1158/0008-5472.CAN-07-5898. View

18.

Segura-Velazquez R, Fragoso G, Sciutto E, Sarukhan A . Towards identification of the mechanisms of action of parasite-derived peptide GK1 on the immunogenicity of an influenza vaccine. Clin Vaccine Immunol. 2009; 16(9):1338-43. PMC: 2745017. DOI: 10.1128/CVI.00106-09. View

19.

Wan Y, Flavell R . How diverse--CD4 effector T cells and their functions. J Mol Cell Biol. 2009; 1(1):20-36. PMC: 2841031. DOI: 10.1093/jmcb/mjp001. View

20.

Lande R, Gilliet M . Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci. 2010; 1183:89-103. DOI: 10.1111/j.1749-6632.2009.05152.x. View